Literature DB >> 31386913

FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study.

Louis Leong-Liung Ling1, Chien-Chin Hsu2, Chee-Chien Yong3, Ahmed M Elsarawy3, Yi-Chia Chan3, Chih-Chi Wang3, Wei-Feng Li3, Ting-Lung Lin3, Fang-Ying Kuo4, Yu-Fan Cheng5, Li-Man Lin6, Chao-Long Chen3, Chih-Che Lin7.   

Abstract

BACKGROUND: Tumor histology affects outcome after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study explores the association between F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) and tumor histology in living donor liver transplantation (LDLT) recipients and their outcome.
MATERIALS AND METHODS: Two hundred fifty-eight patients with primary liver tumors who underwent FDG-PET before LDLT were enrolled in this retrospective study. Unfavorable tumor histology was defined as primary liver tumor other than a well- or moderately differentiated HCC. Thirteen patients had unfavorable tumor histology, including 2 poorly differentiated HCC, 2 sarcomatoid HCC, 5 combined hepatocellular cholangiocarcinoma, 3 intrahepatic cholangiocarcinoma, and 1 hilar cholangiocarcinoma.
RESULTS: FDG-PET positivity was significantly associated with unfavorable tumor histology (P < 0.001). Both FDG-PET positivity and unfavorable tumor histology were significant independent predictors of tumor recurrence and overall survival. In a subgroup analysis of patients with FDG-PET-positive tumors, unfavorable tumor histology was a significant independent predictor of tumor recurrence and overall survival. High FDG uptake (tumor to non-tumor uptake ratio ≥ 2) was a significant predictor of unfavorable tumor histology. Patients with high FDG uptake and/or unfavorable tumors had significantly higher 3-year cumulative recurrence rate (70.8% versus 26.2%, P = 0.004) and worse 3-year overall survival (34.1% versus 70.8%, P = 0.012) compared to those with low FDG uptake favorable tumors.
CONCLUSIONS: The expression of FDG-PET is highly associated with histology of explanted HCC and predicts the recurrence. FDG-PET-positive tumors with high FDG uptake may be considered contraindication for LDLT due to high recurrence rate except when pathology proves favorable histology.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  (18)F-fluorodeoxyglucose; Cholangiocarcinoma; Hepatocellular carcinoma; Liver transplantation; Positron emission tomography

Mesh:

Substances:

Year:  2019        PMID: 31386913     DOI: 10.1016/j.ijsu.2019.07.035

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  3 in total

1.  Proton beam therapy to bridge or downstage locally advanced hepatocellular carcinoma to living donor liver transplantation.

Authors:  Chao-Long Chen; Aldwin D Ong; Jen-Yu Cheng; Chee-Chien Yong; Chih-Che Lin; Chih-Yi Chen; Yu-Fan Cheng
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

2.  Predicting the Recurrence of Hepatocellular Carcinoma after Primary Living Donor Liver Transplantation Using Metabolic Parameters Obtained from 18F-FDG PET/CT.

Authors:  Sungmin Kang; Joo Dong Kim; Dong Lak Choi; Byungwook Choi
Journal:  J Clin Med       Date:  2022-01-12       Impact factor: 4.241

3.  Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.

Authors:  Cheng Zhang; Shi Feng; Zhenhua Tu; Jingqi Sun; Tao Rui; Xueyou Zhang; Haitao Huang; Qi Ling; Shusen Zheng
Journal:  Cancer Med       Date:  2021-07-31       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.